drocamorelin   Click here for help

GtoPdb Ligand ID: 10740

Synonyms: AC01 | HM-01 | HM01
Compound class: Synthetic organic
Comment: Drocamorelin (AC01, formerly HM01) is reported as a brain‐penetrating, orally bioavailable, ghrelin peptidomimetic small-molecule agonist [1]. In preclinical models HM01 stimulates gastrointestinal motility, with effects on gastric inflammation and emptying, that are mediated via central and enteric neurons [2-4]. In the heart drocamorelin acts as a calcium sensitizing inotrope that increases cardiac contractility and force, and for this action it has been proposed for the treatment of chronic heart failure.

The chemical structure of AC01/HM01 was matched to that for the INN drocamorelin, as revealed in WHO INN Proposed List 135 (July 2026).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 44.81
Molecular weight 401.16
XLogP 3.98
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(c(c1Cl)Cl)[C@@H](NC(=O)N([C@@H]1CCN(CC1(C)C)C)C)C
Isomeric SMILES COc1ccc(c(c1Cl)Cl)[C@@H](NC(=O)N([C@@H]1CCN(CC1(C)C)C)C)C
InChI InChI=1S/C19H29Cl2N3O2/c1-12(13-7-8-14(26-6)17(21)16(13)20)22-18(25)24(5)15-9-10-23(4)11-19(15,2)3/h7-8,12,15H,9-11H2,1-6H3,(H,22,25)/t12-,15+/m0/s1
InChI Key WGIAKIIMCPKJQN-SWLSCSKDSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
As AC01, drocamorelin has been progressed as a clinical candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07584967 A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure Phase 2 Interventional AnaCardio AB
NCT05642507 Phase Ib/IIa Trial With AC01 in Patients With HFrEF Phase 1/Phase 2 Interventional AnaCardio AB